CLINICAL SIGNIFICANCE OF TRAIL AND TRAIL RECEPTORS IN PATIENTS WITH HEAD AND NECK CANCER
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, vol.33, no.9, pp.1278-1284, 2011 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 33 Issue: 9
- Publication Date: 2011
- Doi Number: 10.1002/hed.21598
- Journal Name: HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.1278-1284
- Keywords: TRAIL, TRAIL receptor, molecular diagnostics, clinical and pathologic staging, head and neck cancer, APOPTOSIS-INDUCING LIGAND, NF-KAPPA-B, PANCREATIC DUCTAL ADENOCARCINOMA, PROSTATE CARCINOMA-CELLS, GENE-THERAPY, MEDIATED APOPTOSIS, LUNG-CANCER, EXPRESSION, DEATH, SURVIVAL
- Akdeniz University Affiliated: Yes
Abstract
Background. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a death ligand currently under clinical trials for cancer. The molecular profile of TRAIL and TRAIL receptors has not yet been mapped for patients with laryngeal squamous cell carcinoma (SCC) or patients with oral cavity squamous cell carcinoma (OCSCC).